Clinical Issues in Alzheimer’s Disease
Debates and Discussions About Diagnosis, New Therapies, and Healthcare Delivery
Alireza Atri, MD, PhD; Sharon Cohen, MD, FRCPC; Marwan N. Sabbagh, MD, FAAN

Alzheimer’s disease is becoming increasingly prevalent as the general population ages and is expected to affect 14 million people by 2050. As research continues to evolve, new understanding of pathophysiological targets has shaped drug development, leading to the recent approval of an anti-amyloid therapy, with hope that additional targeted therapies will follow. Clinicians must incorporate not only traditional means of assessing cognitive decline in practice, but also advances in biomarker techniques and novel therapies. Faculty will discuss and debate topics related to the pathophysiology of Alzheimer’s disease including implications for treatment targets, best practices for assessing patients with MCI or early-stage disease, the latest clinical profiles and trial evidence for newer targeted therapies, and how to best utilize these treatment options in real-world practice.

This activity is jointly provided by Global Education Group and Integritas Communications. This activity is supported by an educational grant from Biogen MA, Inc.

Clinical Issues™
Debates and Discussions About Diagnosis, New Therapies, and Healthcare Delivery
Sharon Cohen, MD; Marwan Sabbagh, MD
Tuesday
August 16
12:00 PM-
1:15 PM ET
Register Now

credit amount 1.25

Clinical Issues™
Debates and Discussions About Diagnosis, New Therapies, and Healthcare Delivery
Sharon Cohen, MD; Marwan Sabbagh, MD
Tuesday
August 23
3:00 PM-
4:15 PM ET
Register Now

credit amount 1.25